WO2025041806A1 - リボ核酸生産技術 - Google Patents

リボ核酸生産技術 Download PDF

Info

Publication number
WO2025041806A1
WO2025041806A1 PCT/JP2024/029712 JP2024029712W WO2025041806A1 WO 2025041806 A1 WO2025041806 A1 WO 2025041806A1 JP 2024029712 W JP2024029712 W JP 2024029712W WO 2025041806 A1 WO2025041806 A1 WO 2025041806A1
Authority
WO
WIPO (PCT)
Prior art keywords
coli
gene
rna
mrna
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2024/029712
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
直 細田
謙太郎 林
謙爾 柘植
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synplogen Co Ltd
Original Assignee
Synplogen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synplogen Co Ltd filed Critical Synplogen Co Ltd
Priority to JP2025541533A priority Critical patent/JPWO2025041806A1/ja
Publication of WO2025041806A1 publication Critical patent/WO2025041806A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Definitions

  • RNA ribonucleic acid
  • mRNA ribonucleic acid
  • microorganisms such as bacteria for producing mRNA
  • plasmids for producing mRNA using the same
  • mRNA messenger RNA
  • RNA producing plasmid improvement-related (RPPI) genes RNA producing plasmid improvement-related genes
  • pDNA template plasmid DNA
  • the present disclosure provides: (Item 1) Escherichia coli in which one or more RNA producing plasmid improvement-related (RPPI) genes have been disrupted.
  • the RPPI gene is (A) Glucose metabolism (B) Amino acid metabolism (C) Reproduction (D) Homologous recombination (E) Nucleic Acid Biosynthesis The E. coli according to any one of the above items, selected based on one or more factors selected from the group consisting of (F) nucleic acid modification and (G) transporter membrane transport.
  • (Item 3) The Escherichia coli according to any one of the above items, wherein the RPPI gene increases an mRNA synthesis evaluation value when disrupted.
  • (Item 3A) The Escherichia coli according to any one of the above items, in which the mRNA synthesis evaluation value is 1.2 or more when one or more genes are disrupted.
  • (Item 3B) The Escherichia coli according to any one of the above items, in which the mRNA synthesis evaluation value is 1.5 or more when one or more genes are disrupted.
  • (Item 3C) The Escherichia coli according to any one of the above items, in which the mRNA synthesis evaluation value is 2.0 or more when one or more genes are disrupted.
  • the RPPI gene is ECK0337 cynS, ECK0416 xseB, ECK0448 ybaZ, ECK0482 ybbJ, ECK0506 ybbY, ECK0671fur, ECK0797ybiO, ECK0816 moeB, ECK0870 macB, ECK0899 aroA, ECK0974 yccZ, ECK1012 ycdQ, ECK1105 ycfX, ECK1190ycgV, ECK1349 ydaE, ECK1382 feaB, ECK1487 gadB, ECK1505ydeW, ECK1529 ydeI, ECK1548ydfQ, ECK1597 pntB, ECK1648 rnt, ECK1680 sufA, ECK1690ydiB, ECK1701 ydiA, ECK1729 cedA
  • the RPPI gene is ECK0337 cynS, ECK0506 ybbY, ECK0671fur, ECK0797ybiO, ECK0816 moeB, ECK0870 macB, ECK1105 ycfX, ECK1254 trpA, ECK1349 ydaE, ECK1382 feaB, ECK1505ydeW, ECK1597 pntB, ECK1680 sufA, ECK1701 ydiA, ECK1729 cedA, ECK1743 astB, ECK1770ydjH, ECK1834 yebU, ECK1880 flhA, ECK1929 yedF, ECK1949 rcsA, ECK2023ugd, ECK2041 wcaJ, ECK2104 yehD, ECK2123 yehY
  • the RPPI gene is ECK1382 feaB, ECK1597 pntB, ECK1743 astB, ECK1770ydjH, ECK1929 yedF, ECK1949 rcsA, ECK2023ugd, ECK2273 nuoK, ECK2274 nuoJ, ECK3141yhbO, ECK3539 yiaD, ECK3564 yiaK, ECK3733 gidB, and ECK3836 fre The E.
  • the RPPI gene is ECK1382 feaB, ECK1597 pntB, ECK1949 rcsA, ECK2023ugd, ECK2273 nuoK, ECK3141 yhbO, and ECK3564 yiaK
  • (Item 10) The E. coli according to any one of the above items, wherein the E. coli is at least one selected from the group consisting of JM109 strain, DH5 ⁇ strain, BL21 strain, SCS1 strain, XL1-blue strain, HB101 strain, and derivatives thereof.
  • (Item 11) A composition for producing pDNA for RNA production, comprising the E. coli described in any one of the above items.
  • (Item 12) The composition of any one of the above items, wherein the RNA is messenger RNA.
  • (Item 13) A pDNA produced using the Escherichia coli described in any one of the above items or the composition described in any one of the above items.
  • (Item 14) A method for producing pDNA using the E.
  • (Item 18A) A pDNA described in any one of the above items, characterized in that polyA deletion for mRNA production is 50% or less.
  • (Item 19) A composition for producing mRNA comprising a plasmid, wherein the pDNA has less than 50% polyA deletion.
  • (Item 20) A plasmid composition for RNA production produced using the Escherichia coli described in any one of the above items or the composition described in any one of the above items, wherein the composition contains less than 50% pDNA lacking polyA.
  • (Item 21) A method for producing RNA using the pDNA described in any one of the above items or the composition described in any one of the above items.
  • RPPI RNA producing plasmid improvement-related
  • the RPPI gene is ECK0337 (cynS), ECK0416 (xseB), ECK0448 (ybaZ), ECK0482 (ybbJ), ECK0506 (ybbY), ECK0671 (fur), ECK0797 (ybiO), ECK0816 (moeB), ECK0870 (macB), ECK0899 (aroA), ECK097 4 (yccZ), ECK1012 (ycdQ), ECK1105 (ycfX), ECK1190 (ycgV), ECK1254 (trpA), ECK1349 (ydaE), ECK 1382 (feaB), ECK1487 (gadB), ECK1505 (ydeW), ECK1529 (ydeI), ECK1548 (ydfQ), ECK1597 (pntB), E CK1648 (rnt), ECK1680 (sufA), ECK1690 (ydiB), ECK0337 (
  • the present disclosure relates to artificially disrupting or deleting a specific gene in an E. coli production strain, thereby improving the plasmid DNA that serves as a template for mRNA production and producing mRNA with high yields and high quality, and also to the discovery that such a gene exists.
  • the plasmid produced in the E. coli of the present disclosure not only has a high yield of mRNA when used as a template plasmid DNA for producing mRNA, but also has the characteristic that defects are less likely to occur in the production of mRNA with long polyA chains.
  • Long polyA chains are known to increase the stability of mRNA, which also leads to its effectiveness as an mRNA medicine.
  • improvements at the manufacturing stage can be combined with any method, such as mRNA design, transcription reaction, or purification process, that has been investigated so far to increase the yield and quality of mRNA.
  • FIG. 1-1 and FIG. 1-2 are a series of figures showing the results of the same experiment, and may be collectively referred to as FIG. 1.
  • This figure shows the results of synthesizing mRNA using a plasmid prepared from a gene-disrupted strain created using E. coli JM109 as a parent strain as a template, and evaluating the amount of mRNA synthesis and the length of mRNA polyA chain using the fluorescent dye Thioflavin T.
  • the fluorescence measurement value of each E. coli strain was taken as the mRNA synthesis evaluation value when the fluorescence measurement value of the parent strain JM109 strain was taken as 1.
  • Figures 3-1 and 3-2 are a series of figures showing the results of the same experiment, and may be collectively referred to as Figure 3.
  • the figures show the topology verification by agarose electrophoresis of plasmids prepared from 7 strains selected from 90 gene-disrupted strains produced using E. coli JM109 as the parent strain.
  • the results show the results of mini-prep plasmids (left panel) and plasmids prepared by cesium chloride density gradient centrifugation (right panel). Three bands (A, B, C) with different mobilities are detected, and the difference in the amount of these detected reflects the difference in topology.
  • Figures 3-1 and 3-2 are a series of figures showing the results of the same experiment and may be collectively referred to as Figure 3. See Figure 3-1 for legend.
  • Figures 4-1 and 4-2 are a series of figures showing the results of the same experiment, and may be collectively referred to as Figure 4.
  • the figures are diagrams verifying the polyA sequence length of plasmids prepared from 7 strains selected from 90 gene-disrupted strains created using E. coli JM109 as a parent strain. A DNA fragment (490 bp) containing the polyA sequence was verified by agarose electrophoresis (left panel).
  • Figures 4-1 and 4-2 are a series of figures showing the results of the same experiment and may be collectively referred to as Figure 4. See Figure 4-1 for legend. This figure shows the results of an experiment in which mRNA was synthesized using a plasmid prepared from 6 strains selected from 90 gene-disrupted strains produced using the E.
  • RNA producing plasmid improvement-related (RPPI) genes refer to genes that have the effect of increasing the amount of mRNA synthesis and/or lengthening the length of the mRNA polyA chain when mRNA is synthesized from template plasmid DNA produced in a production bacterium (e.g., E. coli) in which the gene has been disrupted.
  • RPPI production bacterium
  • RPPI can be determined using an "mRNA synthesis evaluation value.”
  • the "mRNA synthesis evaluation value” is also called the “mRNA index,” and is set in this disclosure as an index of high yield and high quality in mRNA production. It is an index that evaluates the amount of mRNA synthesis and the length of the mRNA polyA chain together, and can be calculated as a relative value when the value of mRNA transcribed and synthesized from a standard E.
  • coli-derived plasmid is set to 1 by measuring the fluorescence intensity generated by thioflavin T binding to mRNA transcribed and synthesized using a plasmid prepared from a gene-disrupted strain transformed with a plasmid containing an open reading frame (ORF) that codes for a specific protein mRNA (standard E. coli method) (this method is referred to as the standard E. coli method in this specification).
  • ORF open reading frame
  • the measurement method is not limited to this, and any method that can determine the amount of mRNA and the polyA tail length may be used, and any other method that can provide values similar to those of the standard E. coli method may be used.
  • Non-limiting examples of the method for quantifying mRNA include a method using ultraviolet absorption of nucleic acid bases, and a measurement method using RNA-binding fluorescent dyes such as Qubit, SYBR Green II, and RiboGreen.
  • Methods for determining the polyA tail length of mRNA include a method in which the polyA tail portion of mRNA is prepared by RNase T1 treatment or mRNA-binding oligonucleotide and RNase H treatment, and then measured by a bioanalyzer, capillary electrophoresis, or LC-MS. In the present disclosure, if the mRNA synthesis evaluation value exceeds 1, it can be said to be more useful for production than standard E.
  • coli for example, existing strains and derived strains used in production such as the JM109 strain, but from an industrial perspective, it is preferably 1.2 or more, more preferably 1.5 or more, and even more preferably 2.0 or more.
  • RPPI gene is characterized as being related to at least one of the following functions, but the following does not limit the invention of this disclosure: (A) sugar metabolism, (B) amino acid metabolism, (C) replication, (D) homologous recombination, (E) nucleic acid biosynthesis, (F) nucleic acid modification, and (G) transporter membrane transport.
  • sucrose metabolism refers in the narrow sense to the reaction in which sugar is broken down to obtain energy, or the reverse reaction, but in the broad sense typically adopted in this specification it also includes reactions that are indirectly involved in this reaction.
  • the genes related to the above are ECK0671 fur; ECK0870 macB; ECK1105 ycfX; ECK1349 ydaE; ECK1529 ydeI; ECK1597 pntB; ECK1680 sufA; ECK1701 ydiA; ECK1770 ydjH; ECK1788 yeaM; ECK1844 yobB; ECK1929 yedF; ECK1949 rcsA; ECK2010 yeeZ; ECK2023 ugd; ECK2041 wcaJ; ECK2196 napH; ECK2267 yfbN; ECK2273 nuoK; ECK2274 n
  • Examples of such genes include, but are not limited to, uoJ
  • amino acid metabolism refers in the narrow sense to the reaction in which amino acids are broken down to obtain energy, or the reverse reaction, but in the broad sense typically adopted in this specification it also includes reactions that are indirectly involved in this.
  • Genes related to the above include, but are not limited to, ECK0337 cynS; ECK0671 fur; ECK0899 aroA; ECK1012 ycdQ; ECK1254 trpA; ECK1349 ydaE; ECK1382 feaB; ECK1487 gadB; ECK1690 ydiB; ECK1743 astB; ECK1929 yedF; ECK2123 yehY; ECK2267 yfbN; ECK2295 yfcF; ECK2869 hyuA; ECK2952 ansB; ECK3138 yraP; ECK3141 yhbO; ECK3539 yiaD; ECK3606 tdh
  • replication refers in the narrow sense to the self-replication reaction of DNA and the replication reaction of cells, but in the broad sense generally adopted in this specification, it also includes those indirectly involved in this.
  • Genes related to the above include, but are not limited to, ECK0416 xseB; ECK1529 ydeI; ECK1729 cedA; ECK2392 yfeC; ECK2729 pphB; ECK3137 yraO; ECK0337 cynS, etc.
  • homologous recombination refers in the narrow sense to recombination that occurs at sites where DNA base sequences are similar (homologous sites), but in the broad sense generally adopted in this specification, it also includes recombination that is indirectly involved in this.
  • Genes related to the above include, but are not limited to, ECK0416 xseB; ECK2392 yfeC; ECK3137 yraO, etc.
  • nucleic acid biosynthesis refers in the narrow sense to the reaction of synthesizing purine nucleotides or pyrimidine nucleotides in a living organism, but in the broad sense generally adopted in this specification, it also includes those indirectly involved in this reaction.
  • Genes related to the above include, but are not limited to, ECK0506 ybbY; ECK0671 fur; ECK0816 moeB; ECK1648 rnt; ECK1966 yedX; ECK2628 yfjP; ECK2754 ygcK; ECK2959 nupG; ECK3367 yhfW; ECK4233 nrdD.
  • nucleic acid modification refers in a narrow sense to chemical modification such as methylation of nucleic acids that constitute DNA or RNA in a living body, but in the broad sense generally adopted in this specification, it also includes those that are indirectly involved in this.
  • Genes related to the above include, but are not limited to, ECK0448 ybaZ; ECK1834 yebU; ECK2312 truA; ECK2628 yfjP; ECK2754 ygcK; ECK3331 yheM; ECK3733 gidB; ECK4014 yjbC.
  • transporter/membrane transport refers in a narrow sense to membrane transporters that penetrate biological membranes and the transport of substances into and out of cells through these transporters, but in the broad sense generally adopted in this specification, it also includes those that are indirectly involved in this.
  • modification in relation to genes (nucleic acids, proteins, etc.) refers to the insertion of a base sequence into a base sequence (e.g., DNA) within a cell, or the deletion of a portion of a base sequence in RNA or DNA within a cell, or a combination thereof. Destruction is included as one form of modification.
  • a gene is "destroyed" when its function becomes different from normal, and includes complete loss as well as a change of one amino acid or one nucleotide that results in a function different from the original function being exerted.
  • Non-limiting examples of destruction include methods for reducing or eliminating an original function, such as removing the entire length of a gene that codes for a functional protein, removing a portion of the gene, adding a portion to change the function of the protein, or modifying or replacing a portion of the nucleic acid. Also included are methods of destruction outside the region that codes for the protein, such as expression control or silencing by modifying the promoter portion of the gene.
  • Plasmid refers to DNA, usually circular, that exists separately from chromosomes in a cell or exists separately from chromosomes when introduced into a cell, and is also called “plasmid DNA” or "pDNA.” Unless otherwise specified, plasmid may refer to pDNA in this specification. A composition containing a plasmid is called a "plasmid composition.”
  • organism refers to any living system (e.g., animal, fungus, microorganism, or plant) as well as viruses.
  • Organisms include prokaryotes and eukaryotes.
  • Prokaryotes include bacteria, etc.
  • Eukaryotes include unicellular and multicellular eukaryotes.
  • the eukaryote is a multicellular organism, it can be used for parts of the eukaryote (e.g., genes, cells, tissues, organs, etc.).
  • parts of an organism refers to parts of genes, cells, tissues, organs, etc. that make up an organism.
  • RNA production refers to anything intended for the production of RNA.
  • E. coli refers to a gram-negative bacterium with the scientific name Escherichia coli (E. coli). E. coli is used to express proteins by incorporating genes into it, and also to amplify genes by incorporating them into replicable plasmids in E. coli, and for cloning.
  • a "vector” refers to a vector capable of transferring a polynucleotide sequence of interest into a cell of interest.
  • examples of such vectors include those capable of autonomous replication in a host cell such as E. coli or capable of integration into a chromosome, and containing a promoter in a suitable position for transcription of the polynucleotide of the present disclosure.
  • a vector may be an expression vector, a recombinant vector, or the like.
  • a vector is a type of construct, and the present disclosure is provided as a "construct" where appropriate.
  • a "construct" refers to one or more nucleic acids having a certain structure.
  • a "construct” refers to one or more constructs.
  • a construct is not limited to one that is isolated per se, and may refer to a portion having a structure that does not exist in nature that contains a foreign sequence when the foreign sequence is inserted into a longer nucleic acid (e.g., genomic DNA).
  • examples of E. coli include JM109 strain, DH5 ⁇ strain, BL21 strain, SCS1 strain, XL1-blue strain, HB101 strain, and derivatives thereof.
  • a "derived strain” of a specific strain of E. coli is synonymous with a "derived strain” (both are called “derivative” in English), and includes naturally occurring or artificially created substrains and mutants based on the original strain, and such derived strains share basic properties with the original strain.
  • polyA sequence refers to a DNA sequence that directs both the termination and polyadenylation of the nascent RNA transcript. Efficient polyadenylation of recombinant transcripts is desirable because transcripts lacking a polyA tail are unstable and rapidly degraded.
  • introduction of a gene refers to the introduction of an exogenous or endogenous gene, preferably a functional gene, into, for example, a chromosomal genome, etc., by an appropriate introduction technique.
  • a vector such as a phage or a plasmid can be used to introduce the gene.
  • natural transformation, conjugation, protoplast-PEG, electroporation, etc. can also be used.
  • an exogenous functional gene can be introduced by replacing it with an endogenous functional gene.
  • an exogenous functional gene is a gene that does not originally exist in the chromosomal genome of the organism, and can be a gene derived from another organism or a synthetic gene created by PCR or the like. Introduction of a gene also includes conversion of an existing genome into a desired gene by genome editing.
  • operably linked means that the polypeptide encoded by the nucleic acid is linked to an element such as a promoter so that the polypeptide is expressed under the control of the element in a state that exhibits the biological activity of the polypeptide.
  • operably linked sequences include both expression control sequences or regulatory DNA elements adjacent to a gene of interest, and expression control sequences or regulatory DNA elements that act in trans or at a distance to control the gene of interest.
  • production of a substance refers not only to the production of a substance within a cell or organism, but also to the excretion of a substance outside the cell, for example as a culture medium.
  • culture refers to maintaining, propagating (growing), and/or differentiating cells in an in vitro environment.
  • “Culturing” means maintaining, propagating (growing), and/or differentiating cells outside a tissue or outside the body, for example, in a cell culture dish or flask.
  • gene refers to a factor that determines a genetic trait
  • gene can refer to "polynucleotide,” “oligonucleotide,” and “DNA.”
  • Genes that code for such proteins may be endogenous or exogenous to the target organism.
  • these known genes can be used as appropriate. Genes can be used regardless of their origin. That is, genes may originate from organisms of other species or genus than the target organism, or may originate from organisms such as animals, plants, fungi (molds, etc.), and bacteria.
  • genes may be genes encoding proteins having a certain relationship with sequence information disclosed in databases, etc., so long as they have each activity.
  • One such embodiment is a gene that consists of an amino acid sequence in which one or several amino acids are deleted, substituted, inserted or added in the disclosed amino acid sequence, and encodes a protein having an activity to be enhanced in the present disclosure.
  • the amino acid mutations in the disclosed amino acid sequence i.e., deletion, substitution, insertion or addition, may be any one type, or two or more types may be combined.
  • the total number of these mutations is not particularly limited, but is preferably about 1 to 10. More preferably, it is 1 to 5.
  • amino acid substitutions are preferably conservative substitutions, and specifically include substitutions within the following groups: (glycine, alanine) (valine, isoleucine, leucine) (aspartic acid, glutamic acid) (asparagine, glutamine) (serine, threonine) (lysine, arginine) (phenylalanine, tyrosine).
  • RNA refers to a molecule that contains at least one ribonucleotide residue, and preferably is composed entirely or substantially of ribonucleotide residues.
  • “Ribonucleotide” refers to a nucleotide that has a hydroxyl group at the 2' position of a ⁇ -D-ribofuranosyl group.
  • RNA includes isolated RNA, such as double-stranded RNA, single-stranded RNA, partially or completely purified RNA, essentially pure RNA, synthetic RNA, and recombinantly produced RNA, such as modified RNA that differs from naturally occurring RNA by the addition, deletion, substitution and/or modification of one or more nucleotides. Such modifications can include, for example, the addition of non-nucleotide material at one or more nucleotides of the RNA, for example, to the end or internally of the RNA. Nucleotides in an RNA molecule can also include non-standard nucleotides, such as non-naturally occurring or chemically synthesized nucleotides or deoxynucleotides. These modified RNAs can be referred to as analogs or analogs of naturally occurring RNA.
  • RNA includes and preferably relates to "mRNA.”
  • mRNA means "messenger RNA” and relates to a "transcript” that is generated by using a DNA template and that encodes a peptide or polypeptide.
  • an mRNA includes a 5'-UTR, a protein coding region, and a 3'-UTR.
  • UTR is an abbreviation for untranslated region (UTR), and refers to the region on either side of the coding region of mRNA that is not translated into protein. Any UTR may be used, but the 5'UTR includes those encoding GAPDH, HSD17B4, PSMB3, RPL31, RPL32, RPL35, RPL21, Albumin7, LDHB, ACAT2, ATP5A1, Ndufa4, Mp68, NOSIP, SLC7A3, TUBB4B, UBQLN2, mRPL35A, mRPL21, AIG1, COX6C, ⁇ -globin, ⁇ -globin, RPS8, TOP, MCP-1, RPL12s.c.
  • the 3'UTR may be selected from GAPDH, Albumin, LDHB, ACAT2, ⁇ -globin, ⁇ -globin, PSMB3, CASP1, COX6B1, GNAS, NDUFA1, and RPS9, histone stem loop, or a natural or artificial sequence having complementarity with the 5'UTR.
  • the UTRs may include a non-complementary portion and a complementary portion to the other UTR, and the non-complementary portion and the complementary portion may be present alternately.
  • the complementarity is preferably 40% or more and 90% or less (for example, 40%, 50%, 60%, 70%, 80%, 90% or a range therebetween, but is not limited thereto), and more preferably 75% or more.
  • all of the non-complementary portions are 1-base substitutions, and the complementary portions are each independently 3-7 bases long (e.g., 3, 4, 5, 6, or 7 bases long); the non-complementary portions are 2-base substitutions, and the complementary portions are each independently 5-7 bases long (e.g., 5, 6, or 7 bases long); the non-complementary portions are 2-base removals, and the complementary portions are each independently 5-11 bases long (e.g., 5, 6, 7, 8, 9, 10, or 11 bases long); the non-complementary portions are 3-base substitutions, and the complementary portions are each independently 8-9 bases long (e.g., 8 or 9 bases long); and the non-complementary portions are 3-base removals, and the complementary portions are each independently 8-11 bases long (e.g., 8, 9, 10, or 11 bases long).
  • a polyA chain may be selected for the 3' end of the 3'UTR. This polyA tail functions to improve mRNA stability and translation efficiency.
  • non-complementary portion refers to a portion that is not complementary in the base sequence
  • complementary portion refers to a portion that is complementary in the base sequence.
  • complementary portions and non-complementary portions can be specified in units of one base.
  • each non-complementary portion is all one base
  • the length of each non-complementary portion means that when a complementary portion and a non-complementary portion are specified in a portion of a target nucleic acid, if there is a single non-complementary portion, it is one base long, and if there are multiple non-complementary portions, all of the multiple non-complementary portions are one base long.
  • either the 5'UTR or the 3'UTR may be 0 bases long.
  • deletions, substitutions, and additions will be determined by comparing the nucleic acids in order starting from the 5' end.
  • mRNA may be produced by in vitro transcription from a DNA template.
  • In vitro transcription methods are known to those of skill in the art.
  • a variety of in vitro transcription kits are commercially available.
  • EK0337 (cynS) ECK0337
  • EK0337 ECK0337
  • cynS ECK0337
  • cynS cynS
  • ECK*** (XXXX) is sometimes written in a compound form as "ECK*** XXXX” or in other formats, but these are synonymous.
  • EK0416 (xseB) ECK0416 (xseB)
  • EK0416 ECK0416
  • xseB a gene encoding the exodeoxyribonuclease 7 small subunit of Escherichia coli, and are synonymous with yajE, JW0412, b0422, etc., and correspond to P0A8G9 in UniProtKB (Swiss-Prot).
  • EK0482 (ybbJ) ECK0482 (ybbJ)
  • EK0482 ECK0482
  • ybbJ ECK0482
  • ybbJ ECK0482
  • EK0506(ybbY) ECK0506(ybbY)
  • EK0506 ECK0506
  • ybbY a gene encoding a protein presumed to be a purine permease of Escherichia coli, and are synonymous with glxB4, JW0501, b0513, etc., and correspond to P77328 in UniProtKB (Swiss-Prot).
  • EK0671(fur) ECK0671
  • EK0671 ECK0671 or “fur” are all used interchangeably and have the same meaning, and are a gene that codes for the iron uptake regulation protein of Escherichia coli, and are synonymous with JW0669, b0683, etc., and correspond to P0A9A9 in UniProtKB (Swiss-Prot).
  • EK0797(ybiO) ECK0797
  • ECK0797 ECK0797
  • ybiO a gene encoding a moderate conductance mechanosensitive channel of Escherichia coli, and are synonymous with JW7093, JW5108, b0808, etc., and correspond to P75783 in UniProtKB (Swiss-Prot).
  • EK0797 is a gene predicted to encode the moderate conductance mechanosensitive channel YbiO (YbiO) of Escherichia coli, and is synonymous with JW0793, JW5108, b0808, etc., and corresponds to P75783 in UniProtKB (Swiss-Prot).
  • EK0816 (moeB) ECK0816
  • ECK0816 ECK0816
  • moeB ECK0816
  • chlN molybdopterin synthase adenylyltransferase of Escherichia coli
  • chlN molybdopterin synthase adenylyltransferase of Escherichia coli
  • EK0870 (macB)
  • ECK0870 or “macB” are all used interchangeably and have the same meaning, and are a gene encoding the macrolide export ATP-binding/permease protein of E. coli, and are synonymous with ybjZ, JW0863, b0879, etc., and correspond to P75831 in UniProtKB (Swiss-Prot).
  • EK0899(aroA) ECK0899
  • ECK0899 aroA
  • aroA aroA
  • EK0974(yccZ) ECK0974(yccZ)
  • EK0974 ECK0974
  • yccZ a gene that encodes a protein presumed to be a polysaccharide export protein of E. coli, and is synonymous with gfcE, JW0966, b0983, etc., and corresponds to P0A932 in UniProtKB (Swiss-Prot).
  • EK1012(ycdQ) ECK1012
  • ECK1012 ECK1012
  • ycdQ a gene encoding poly-beta-1,6-N-acetyl-D-glucosamine synthase of Escherichia coli, and are synonymous with pgaC, JW1007, b1022, etc., and correspond to P75905 in UniProtKB (Swiss-Prot).
  • EK1105(ycfX) ECK1105" and "ycfX” are all used interchangeably and have the same meaning, and are a gene encoding N-acetyl-D-glucosamine kinase of Escherichia coli, synonymous with nagK, JW1105, b1119, etc., and corresponding to P75959 in UniProtKB (Swiss-Prot).
  • EK1190 (ycgV) ECK1190
  • ECK1190 ycgV
  • ECK1190 ECK1190
  • ycgV ECK1190
  • EK1254(trpA) ECK1254(trpA)
  • EK1254" or trpA are all used interchangeably and have the same meaning, and are a gene that codes for the tryptophan synthase alpha chain of Escherichia coli, and are synonymous with JW1252, b1260, etc., and correspond to P0A877 in UniProtKB (Swiss-Prot).
  • EK1349 (ydaE) ECK1349 or “ydaE” are all used interchangeably and have the same meaning, and are a gene encoding an uncharacterized protein (Uncharacterized protein YdaE) of E. coli, a conserved protein derived from the Rac prophage (Rac prophage; conserved protein), synonymous with JW1346, b4526, etc., and corresponding to P38394 in UniProtKB (Swiss-Prot).
  • EK1382(feaB) ECK1382
  • ECK1382 ECK1382
  • feaB a gene encoding phenylacetaldehyde dehydrogenase in Escherichia coli, and are synonymous with maoB, padA, ydbG, JW1380, b1385, etc., and correspond to P80668 in UniProtKB (Swiss-Prot).
  • EK1487(gadB) ECK1487
  • ECK1487 ECK1487
  • gadB a gene encoding glutamate decarboxylase beta of Escherichia coli, and are synonymous with JW1488, b1493, etc., and correspond to P69910 in UniProtKB (Swiss-Prot).
  • EK1505(ydeW) "ECK1505" and “ydeW” are all used interchangeably and have the same meaning, and are a gene that encodes the transcriptional regulator LsrR of Escherichia coli, and are synonymous with lsrR, JW1505, b1512, etc., and correspond to P76141 in UniProtKB (Swiss-Prot).
  • EK1529(ydeI) "ECK1529” or “ydeI” are all used interchangeably and have the same meaning, and are a gene that codes for a conserved protein (conserved protein) of E. coli as an uncharacterized protein (Uncharacterized protein YdeI), and is synonymous with JW1529, b1536, etc., and corresponds to P31130 in UniProtKB (Swiss-Prot).
  • EK1548(ydfQ) ECK1548
  • ECK1548 ECK1548
  • ydfQ a gene encoding a protein that may be a probable prophage lysozyme in E. coli, and are synonymous with rrrQ, arrQ, JW1546, b1554, etc., and correspond to P76159 in UniProtKB (Swiss-Prot).
  • EK1597(pntB) ECK1597
  • ECK1597 ECK1597
  • pntB a gene encoding the NAD(P) transhydrogenase subunit beta of Escherichia coli, and are synonymous with JW1594, b1602, etc., and correspond to P0AB67 in UniProtKB (Swiss-Prot).
  • EK1648(rnt) ECK1648
  • rnt a gene encoding Escherichia coli ribonuclease T, belonging to the DNA polymerase III epsilon subunit, synonymous with JW1644, b1652, etc., and corresponding to P30014 in UniProtKB (Swiss-Prot).
  • EK1680 (sufA)
  • EK1680 or “sufA” are all used interchangeably and have the same meaning, and are a gene encoding the protein SufA (Protein SufA) of Escherichia coli, which belongs to the iron-sulfur cluster assembly protein, is synonymous with ydiC, JW1674, b1684, etc., and corresponds to P77667 in UniProtKB (Swiss-Prot).
  • EK1690 (ydiB) ECK1690
  • ECK1690 ECK1690
  • ydiB ECK1690
  • ydiB a gene encoding quinate/shikimate dehydrogenase in Escherichia coli, which corresponds to P0A6D5 in UniProtKB (Swiss-Prot).
  • EK1701 (ydiA) ECK1701
  • EK1701 or ydiA are all used interchangeably and have the same meaning, and are a gene encoding the phosphoenolpyruvate synthase regulatory protein of Escherichia coli, and are synonymous with ppsR, JW1693, b1703, etc., and correspond to P0A8A4 in UniProtKB (Swiss-Prot).
  • EK1729(cedA) ECK1729
  • EK1729 ECK1729 or “cedA” are all used interchangeably and have the same meaning, and are a gene that encodes the cell division activator CedA of Escherichia coli, and is synonymous with ydjP, JW1720, b1731, etc., and corresponds to P0AE60 in UniProtKB (Swiss-Prot).
  • ECK1743(astB) ECK1743
  • ECK1743 ECK1743
  • astB ECK1743
  • ECK1752 (ynjB) ECK1752
  • ECK1752 ECK1752
  • ynjB ECK1752
  • EK1770 (ydjH) "ECK1770” or “ydjH” are all used interchangeably and have the same meaning, and are a gene encoding the uncharacterized sugar kinase YdjH (Uncharacterized sugar kinase YdjH) of Escherichia coli, which is a member of the hexokinase family and is synonymous with JW5289, b1772, etc., and corresponds to P77493 in UniProtKB (Swiss-Prot).
  • EK1788(yeaM) ECK1788
  • ECK1788 ECK1788
  • yeaM a gene encoding the HTH-type transcriptional regulator NimR of Escherichia coli, and are synonymous with nimR, JW1779, b1790, etc., and correspond to P76241 in UniProtKB (Swiss-Prot).
  • EK1834 (yebU) ECK1834" and “yebU” are all used interchangeably and have the same meaning, and are a gene predicted to encode Escherichia coli ribosomal RNA small subunit methyltransferase F, and are synonymous with JW1824, JW5301, b1835, etc., and correspond to P76273 in UniProtKB (Swiss-Prot).
  • EK1844 (yobB) ECK1844" or “yobB” are all used interchangeably and have the same meaning, and are a gene that encodes a conserved protein of E. coli known as the uncharacterized protein YobB (Uncharacterized protein YobB), and is synonymous with JW1832, b1843, etc., and corresponds to P76280 in UniProtKB (Swiss-Prot).
  • EK1880 (flhA) ECK1880
  • ECK1880 ECK1880
  • flhA a gene that encodes the flagellar biosynthesis protein FlhA (FlhA) of Escherichia coli, and are synonymous with JW1868, b1879, etc., and correspond to P76298 in UniProtKB (Swiss-Prot).
  • EK1929 (yedF)
  • EK1929 or “yedF” are all used interchangeably and have the same meaning, and are a gene encoding a protein presumed to be the putative sulfur carrier protein YedF of Escherichia coli, and are synonymous with JW1915, b1930, etc., and correspond to P0AA31 in UniProtKB (Swiss-Prot).
  • EK1949 (rcsA) ECK1949
  • rcaA a gene that codes for the E. coli transcriptional regulatory protein RcsA, and are synonymous with JW1935, b1951, etc., and correspond to P0DMC9 in UniProtKB (Swiss-Prot).
  • EK1966(yedX) ECK1966
  • ECK1966 ECK1966
  • yedX a gene encoding 5-hydroxyisourate hydrolase of Escherichia coli, and are synonymous with hiuH, JW1953, b1970, etc., and correspond to P76341 in UniProtKB (Swiss-Prot).
  • EK2010(yeeZ) ECK2010(yeeZ)
  • EK2010 ECK2010
  • yeeZ a gene encoding a protein predicted to be an epimerase with an NAD(P)-binding Rossmann-fold domain in Protein YeeZ of Escherichia coli, and are synonymous with JW1998, b2016, etc., and correspond to P0AD12 in UniProtKB (Swiss-Prot).
  • EK2023(ugd) ECK2023(ugd)
  • EK2023 ECK2023 and “ugd” are all used interchangeably and have the same meaning, and are a gene encoding UDP-glucose 6-dehydrogenase of Escherichia coli, synonymous with pmrE, udg, yefA, JW2010, b2028, etc., and corresponding to P76373 in UniProtKB (Swiss-Prot).
  • EK2041(wcaJ) ECK2041(wcaJ)
  • EK2041 ECK2041
  • wcaJ a gene encoding UDP-glucose:undecaprenyl-phosphate glucose-1-phosphate transferase of Escherichia coli, and are synonymous with JW2032, b2047, etc., and correspond to P71241 in UniProtKB (Swiss-Prot).
  • EK2104 (yehD) "ECK2104" or “yehD” are all used interchangeably and have the same meaning, and are a gene that encodes the uncharacterized flagellar-like protein YehD (Uncharacterized fimbrial-like protein YehD) of E. coli, which belongs to the fimbrial subunit elfa-related and is synonymous with JW2098, b2111, etc., and corresponds to P33343 in UniProtKB (Swiss-Prot).
  • EK2123(yehY) ECK2123(yehY)
  • EK2123 ECK2123 or “yehY”
  • glxB4 JW0501, b0513, etc.
  • ECK2193 (ccma) ECK2193
  • ECK2193 ccma
  • ccma a gene that encodes a protein presumed to be a putative purine permease of Escherichia coli, and is synonymous with JW2118, b2130, etc., and corresponds to P33931 in UniProtKB (Swiss-Prot).
  • EK2196 (napH) ECK2196
  • ECK2196 ECK2196
  • napH a gene that encodes the ferredoxin-type protein NapH of Escherichia coli, and are synonymous with yejZ, JW2192, b2204, etc., and correspond to P33934 in UniProtKB (Swiss-Prot).
  • EK2267(yfbN) "ECK2267” or “yfbN” are all used interchangeably and have the same meaning, and are a gene assumed to code for the uncharacterized protein YfbN of E. coli, and are synonymous with JW2268, b2273, etc., and correspond to P76484 in UniProtKB (Swiss-Prot).
  • ECK2273 (nuoK) ECK2273
  • ECK2273 ECK2273
  • nuoK a gene that encodes the NADH-quinone oxidoreductase subunit K of Escherichia coli, and are synonymous with JW2274, b2279, etc., and correspond to P0AFE4 in UniProtKB (Swiss-Prot).
  • EK2274(nuoJ) ECK2274(nuoJ)
  • EK2274 ECK2274
  • nuoJ a gene encoding * (NADH-quinone oxidereductase subunit J) of Escherichia coli, and are synonymous with JW2275b2280, etc., and correspond to P0AFE0 in UniProtKB (Swiss-Prot).
  • EK2295 (yfcF) ECK2295
  • ECK2295 ECK2295
  • yfcF a gene encoding the glutathione S-transferase YfcF of Escherichia coli, and are synonymous with JW2298, b2301, etc., and correspond to P77544 in UniProtKB (Swiss-Prot).
  • EK2312 (truA) ECK2312
  • ECK2312 ECK2312
  • trueA a gene encoding tRNA pseudouridine synthase A of Escherichia coli, and are synonymous with asuC, hisT, leuK, JW2315, b2318, etc., and correspond to P07649 in UniProtKB (Swiss-Prot).
  • EK2392 (yfeC) ECK2392 (yfeC)
  • EK2392 ECK2392
  • yfeC a gene encoding an uncharacterized protein (Uncharacterized protein YfeC) of Escherichia coli, a protein assumed to be a predicted DNA-binding transcriptional regulator, synonymous with JW2393, b2398, etc., and corresponding to P0AD37 in UniProtKB (Swiss-Prot).
  • EK2404 (yfeH)
  • EK2404" ECK2404" or “yfeH” are all used interchangeably and have the same meaning, and are a gene that encodes a protein assumed to be the symporter protein YfeH (putative symporter YfeH) of Escherichia coli, which belongs to solute carrier family 10 member 7, is synonymous with JW5876, b2410, etc., and corresponds to P39836 in UniProtKB (Swiss-Prot).
  • EK2628 (yfjP)
  • ECK2628 means that "ECK2628” or “yfjP” are used interchangeably and have the same meaning, and is a gene predicted to encode a GTP-binding protein as the uncharacterized protein YfjP (Uncharacterized protein YfjP) of Escherichia coli, and is synonymous with JW2613, JW5419, b2632, etc., and corresponds to P52131 in UniProtKB (Swiss-Prot).
  • EK2660 (yqaE)
  • EK2660 ECK2660
  • yqaE a gene encoding the UPF0057 membrane protein YqaE of Escherichia coli, which belongs to the hydrophobic protein rci2 low temperature and salt responsive protein lti6-related, is synonymous with JW2641, b2666, etc., and corresponds to P0AE42 in UniProtKB (Swiss-Prot).
  • EK2674 (ygaX)
  • EK2674 ECK2674
  • ygaX UniProtKB
  • EK2706(norW) ECK2706
  • ECK2706 ECK2706
  • norW a gene encoding the nitric oxide reductase FIRd-NAD(+) reductase of E. coli, which belongs to the fad-dependent oxidereductase family and is synonymous with flrR, ygbD, JW2681, b2711, etc., and corresponds to P37596 in UniProtKB (Swiss-Prot).
  • ECK2709(ascG) ECK2709
  • ECK2709 ECK2709 or “ascG” are all used interchangeably and have the same meaning, and are a gene encoding the HTH-type transcriptional regulator AscG of Escherichia coli, which belongs to the laci-related transcriptional repressor, is synonymous with JW5434, b2714, etc., and corresponds to P24242 in UniProtKB (Swiss-Prot).
  • EK2729 (pphB) ECK2729
  • pphB a gene encoding serine/threonine-protein phosphatase 2 of Escherichia coli, which belongs to metallophosphoesterase and is synonymous with prpB, ygbH, JW2704, b2734, etc., and corresponds to P55799 in UniProtKB (Swiss-Prot).
  • ECK2754 ygcK
  • ECK2754 ECK2754
  • ygcK a gene encoding the CRISPR system cascade subunit CasB of Escherichia coli, and are synonymous with casB, cse2, JW2729, b2759, etc., and correspond to P76632 in UniProtKB (Swiss-Prot).
  • EK2869 (hyuA)
  • EK2869 or “hyuA” are all used interchangeably and have the same meaning, and are a gene of Escherichia coli that codes for D-phenylhydantoinase, are a member of the hydrantoinase/dihydropyrimidinase family, are synonymous with ygeZ, JW2841, b2873, etc., and correspond to Q46806 in UniProtKB (Swiss-Prot).
  • EK2897 (ygfF)
  • EK2897 or “ygfF” are all used interchangeably and have the same meaning, and are a gene encoding the uncharacterized oxidoreductase YgfF (Uncharacterized oxidoreductase YgfF) of Escherichia coli, which belongs to the oxidoreductase, short-chain dehydrogenase/reductase family (afu_orthologue afua_5g02870), is synonymous with yqfD, JW2870, b2902, etc., and corresponds to P52037 in UniProtKB (Swiss-Prot).
  • afu_orthologue afua_5g02870 short-chain dehydrogenase/reductase family
  • EK2952(ansB) ECK2952
  • EK2952 ECK2952
  • ansB a gene encoding L-asparaginase 2 of Escherichia coli, synonymous with JW2924, b2957, etc., and corresponding to P00805 in UniProtKB (Swiss-Prot).
  • EK2959 (nupG) is a gene that codes for the nucleoside permease NupG of Escherichia coli, belong to the bll5896 protein, are synonymous with JW2932, b2964, etc., and correspond to P0AFF4 in UniProtKB (Swiss-Prot).
  • ECK3003 (yqhD) ECK3003
  • ECK3003 ECK3003
  • yqhD a gene that codes for alcohol dehydrogenase YqhD of Escherichia coli, and are synonymous with JW2978, b3011, etc., and correspond to Q46856 in UniProtKB (Swiss-Prot).
  • EK3085 (exuR) is a gene that codes for an Exu regulon transcriptional regulator of Escherichia coli, belong to the transcriptional regulator, gntr family, are synonymous with JW3065, b3094, etc., and correspond to P0ACL2 in UniProtKB (Swiss-Prot).
  • EK3133 (yraK) "ECK3133” and “yraK” are all used interchangeably and have the same meaning, and are a gene that codes for the uncharacterized fimbrial-like protein YraK (Uncharacterized Fimbrial-like Protein YraK) of Escherichia coli, which belongs to the fimbrial subunit elfa-related and is synonymous with JW3114, b3145, etc., and corresponds to P43319 in UniProtKB (Swiss-Prot).
  • EK3137(yraO) ECK3137
  • ECK3137 ECK3137
  • yraO a gene encoding the DnaA initiator-associating protein DiaA of Escherichia coli, which belongs to the sedoheptulose 7-phosphate isomerase/dnaa initiator-associating factor for replication initiation, and is synonymous with yraO, JW3118, b3149, etc., and corresponds to P66817 in UniProtKB (Swiss-Prot).
  • ECK3138(yraP) ECK3138
  • ECK3138 ECK3138
  • yraP a gene that codes for the outer membrane lipoprotein
  • DolP of Escherichia coli belong to the bon domain-containing protein, are synonymous with dolP, JW3119, b3150, etc., and correspond to P64596 in UniProtKB (Swiss-Prot).
  • EK3139 (yraQ) ECK3139
  • ECK3139 ECK3139
  • yraQ a gene that encodes the UPF0718 protein YraQ (UPF0718 protein YraQ) of Escherichia coli, and are synonymous with JW3120, b3151, etc., and correspond to P45468 in UniProtKB (Swiss-Prot).
  • EK3141(ybbO) ECK3141(ybbO)
  • EK3141 ECK3141
  • ybbO a gene that encodes a protein presumed to be a putative purine permease of Escherichia coli, and is synonymous with glxB4, JW0501, b0513, etc., and corresponds to P0AFP4 in UniProtKB (Swiss-Prot).
  • ECK3319(gspK) ECK3319 or “gspK” are all used interchangeably and have the same meaning, and are a gene encoding a protein presumed to be type II secretion system protein K of Escherichia coli, and are synonymous with glxB4, JW0501, b0513, etc., and correspond to P45762 in UniProtKB (Swiss-Prot).
  • EK3331(yheM) ECK3331
  • ECK3331 ECK3331
  • yheM a gene that encodes the protein TusC of Escherichia coli, and are synonymous with tusC, JW3306, b3344, etc., and correspond to P45531 in UniProtKB (Swiss-Prot).
  • EK3346 (ybeH) ECK3346
  • ECK3346 ECK3346
  • ybeH a gene encoding a protein presumed to be Escherichia coli protein YbeH (putative protein YbeH), and are synonymous with b4581, JW0620, b0625, etc., and correspond to P0DP63 in UniProtKB (Swiss-Prot).
  • EK3367 (yhfW) "ECK3367” and “yhfW” are all used interchangeably and have the same meaning, and are a gene that codes for the uncharacterized protein YhfW (Uncharacterized protein YhfW) of E. coli, which belongs to the phosphopentomutase family and is synonymous with JW3343, b3380, etc., and corresponds to P45549 in UniProtKB (Swiss-Prot).
  • EK3513(dctA) ECK3513
  • ECK3513 ECK3513
  • dctA dctA
  • EK3526 (yhjV)
  • EK3526 ECK3526
  • yhiV a gene that codes for the inner membrane transport protein YhjV of Escherichia coli, which belongs to the serine transporter family and is synonymous with JW3508, b3539, etc., and corresponds to P37660 in UniProtKB (Swiss-Prot).
  • ECK3539 (yiaD) ECK3539
  • ECK3539 ECK3539
  • yiaD ECK3539
  • ECK3539 ECK3539
  • yiaD ECK3539
  • ECK3539 ECK3539
  • yiaD ECK3539
  • ECK3539 ECK3539
  • yiaD ECK3539
  • ECK3564 (yiaK)
  • ECK3564 and “yiaK” are all used interchangeably and have the same meaning, and are a gene encoding 2,3-diketo-L-gulonate reductase of Escherichia coli, belonging to the oxidoreductase-related group, synonymous with dlgD, JW3547, b3575, etc., and corresponding to P37672 in UniProtKB (Swiss-Prot).
  • EK3606(tdh) ECK3606
  • tdh a gene encoding L-threonine 3-dehydrogenase of Escherichia coli, and are synonymous with JW3591, b3616, etc., and correspond to P07913 in UniProtKB (Swiss-Prot).
  • EK3683 (dgoT)
  • EK3683 or “dgoT” are all used interchangeably and have the same meaning, and are a gene that codes for the D-galactonate transporter of Escherichia coli, belong to solute carrier family 17, are synonymous with yidT, JW5859, b3691, etc., and correspond to P0AA76 in UniProtKB (Swiss-Prot).
  • ECK3733 (gidB) ECK3733
  • ECK3733 ECK3733
  • gidB a gene encoding ribosomal RNA small subunit methyltransferase G of Escherichia coli, which belongs to the s-adenosyl-l-methionine-dependent methyltransferases superfamily protein, is synonymous with rsmG, JW3718, b3740, etc., and corresponds to P0A6U5 in UniProtKB (Swiss-Prot).
  • EK3836(fre) genes encoding the NAD(P)H-flavin reductase of Escherichia coli, belong to the Na(+)-translocating NADH-quinone reductase subunit, and are synonymous with fadI, flrD, fsrC, ubiB, JW3820, b3844, etc., and correspond to P0AEN1 in UniProtKB (Swiss-Prot).
  • EK3868(ompL) ECK3868
  • ECK3868 ECK3868
  • ompL a gene that codes for the porin OmpL of Escherichia coli, which belongs to the outer membrane protein-related-related group and is synonymous with yshA, JW3846, b3875, etc., and corresponds to P76773 in UniProtKB (Swiss-Prot).
  • EK3893 (frvA) ECK3893
  • ECK3893 ECK3893
  • frvA frvA
  • ECK4014 (yjbC) ECK4014" or “yjbC” are all used interchangeably and have the same meaning, and are a gene encoding the dual-specificity RNA pseudouridine synthase RluF of Escherichia coli, which belongs to the mitochondrial RNA pseudouridine synthase, is synonymous with yjbC, JW3982, b4022, etc., and corresponds to P32684 in UniProtKB (Swiss-Prot).
  • ECK4017(pgi) ECK4017
  • ECK4017 ECK4017
  • pgi a gene encoding glucose-6-phosphate isomerase of Escherichia coli, synonymous with JW3985, b4025, etc., and corresponding to P0A6T1 in UniProtKB (Swiss-Prot).
  • EK4034 (dgkA) ECK4034
  • ECK4034 dgkA
  • ECK4034 dgkA
  • ECK4034 dgkA
  • dgkA UniProtKB
  • EK4112 (melA) ECK4112
  • ECK4112 ECK4112
  • melA a gene encoding alpha-galactosidase of Escherichia coli, belonging to 6-phospho-beta-glucosidase-related, synonymous with mel-7, JW4080, b4119, etc., and corresponding to P06720 in UniProtKB (Swiss-Prot).
  • EK4207(ytfG) ECK4207
  • ECK4207 ECK4207
  • ytfG a gene encoding quinone oxidoreductase 2 of Escherichia coli, and are synonymous with qorB, qor2, JW4169, b4211, etc., and correspond to P39315 in UniProtKB (Swiss-Prot).
  • EK4233 (nrdD) ECK4233 (nrdD)
  • EK4233 ECK4233 or “nrdD” are all used interchangeably and have the same meaning, and are a gene encoding anaerobic ribonucleoside triphosphate reductase of Escherichia coli, and are synonymous with JW4197, b4238, etc., and correspond to P28903 in UniProtKB (Swiss-Prot).
  • the present disclosure provides an E. coli strain in which one or more RNA producing plasmid improvement-related (RPPI) genes have been disrupted.
  • RPPI RNA producing plasmid improvement-related
  • the present disclosure provides a composition for producing a plasmid for producing RNA. That is, the present disclosure also provides a composition for producing a plasmid for producing RNA, comprising E. coli in which one or more RNA producing plasmid improvement-related (RPPI) genes have been disrupted.
  • RPPI RNA producing plasmid improvement-related
  • the present disclosure provides the use of E. coli in which one or more RNA producing plasmid improvement-related (RPPI) genes have been disrupted, for producing a plasmid for RNA production.
  • RPPI RNA producing plasmid improvement-related
  • the present disclosure provides a method for producing a plasmid for RNA production, comprising a step of culturing Escherichia coli in which one or more RNA producing plasmid improvement-related (RPPI) genes have been disrupted.
  • this method can comprise a step of introducing a vector into the Escherichia coli and a step of culturing the Escherichia coli.
  • RNA producing plasmid improvement-related (RPPI) genes are genes that, when disrupted or deleted, improve the plasmid DNA that serves as the template for mRNA production for use in mRNA production, allowing high-yield, high-quality mRNA to be produced.
  • RPPI plasmid improvement-related
  • the template plasmid DNA has the property of being able to produce high-yield, high-quality mRNA. Not only is the yield of mRNA high, but the transcribed mRNA has a long polyA chain and is characterized by little deletion. Long polyA chains are known to increase the stability and translation efficiency of mRNA, which also leads to its effectiveness as an mRNA medicine.
  • improvements at the manufacturing stage can be combined with any method, such as mRNA design, transcription reaction, or purification process, that has been investigated to increase the yield and quality of mRNA, and exert beneficial effects and functions when producing mRNA that can be applied to a variety of technologies.
  • E. coli with a disrupted RPPI gene is provided by disrupting one or more of the genes identified in this disclosure using gene modification techniques described herein or known in the art, and such E. coli may be produced or prepared prior to use using the following techniques, or may be obtained from another source.
  • E. coli with a disrupted RPPI gene it can be produced as follows.
  • a commonly available E. coli strain can be obtained and the translation region of the RPPI gene to be disrupted can be replaced with a kanamycin resistance gene or a chloramphenicol resistance gene to create E. coli in which the RPPI gene has been disrupted.
  • the RPPI gene can be disrupted by any method, such as removing part of the translation region, adding a part to change the function of the protein, or modifying or replacing a part of the nucleic acid. It can also be disrupted outside the translation region that codes for the protein, for example by expression control or silencing through modification of the promoter part of the gene, and references such as Hirotada Mori, Masakazu Kataoka, Xi Yang, Microorganisms. 2022, 10, 1835; Yamada Masami, Environ. Mutagen Res., 2003, 25, 87-92 can be referred to.
  • the RPPI gene can be provided as follows:
  • the RPPI gene will be contained therein.
  • the RPPI gene-disrupted E. coli can be used as follows. For example, a plasmid incorporating a template DNA encoding a target mRNA is amplified in Escherichia coli in which the RPPI gene has been destroyed, and then the plasmid is extracted and linearized, after which mRNA is transcribed and synthesized by the In Vitro Transcription (IVT) method, thereby making it possible to obtain pharmaceutical mRNA in high yield and with high quality.
  • IVTT In Vitro Transcription
  • the E. coli of the present disclosure is JM109 strain, DH5 ⁇ strain, BL21 strain, SCS1 strain, XL1-blue strain, HB101 strain, or a derivative thereof, but is not limited to the E. coli of the present disclosure, and any E. coli strain generally used for production can be used.
  • any of the strains and derivatives shown in Biotechnol. J. 2012, 7, 251-261 Figure 2 can be used.
  • the E. coli includes one or more of the following genes disrupted as RPPI genes: ECK0337 cynS; ECK0416 xseB; ECK0448 ybaZ; ECK0482 ybbJ; ECK0506 ybbY; ECK0671 fur; ECK0797 ybiO; ECK0816 moeB; ECK0870 macB; ECK0899 aroA; ECK0974 yccZ; ECK1012 ycdQ; ECK1105 ycfX; ECK1190 ycgV; ECK1254 trpA; ECK1349 ydaE; ECK1382 feaB; ECK1487 gadB; ECK1505 ydeW ...
  • E. coli gene disruptant strains had an mRNA synthesis evaluation value of 1.2 times or more compared to the parent strain JM109.
  • an mRNA synthesis evaluation value of more than 1 can be said to be more useful for production than existing strains and derived strains, but the following 48 strains are more preferable: ECK0337 cynS; ECK0506 ybbY; ECK0671 fur; ECK0797 ybiO; ECK0816 moeB; ECK0870 macB; ECK1105 ycfX; ECK1254 trpA; ECK1349 ydaE; ECK1382 feaB; ECK1505 ydeW; ECK1597 pntB; ECK1680 sufA; ECK1701 ydiA; ECK1729 cedA; ECK1743 as tB; ECK1770 ydjH; ECK1834 yeb
  • the production is highly reproducible and stable, and examples of such strains include the following 14 strains: a disruptant of a gene selected from the group consisting of ECK1382 feaB; ECK1597 pntB; ECK1743 astB; ECK1770 ydjH; ECK1929 yedF; ECK1949 rcsA; ECK2023 ugd; ECK2273 nuoK; ECK2274 nuoJ; ECK3141 yhbO; ECK3539 yiaD; ECK3564 yiaK; ECK3733 gidB; and ECK3836 fre.
  • a disruptant of a gene selected from the group consisting of ECK1382 feaB; ECK1597 pntB; ECK1743 astB; ECK1770 ydjH; ECK1929 yedF; ECK1949 rcsA; ECK2023 ugd; ECK2273 nuo
  • the strains have higher productivity and/or less deletion of polyA tails, and examples of such strains include the following seven strains: ECK1382 feaB; ECK1597 pntB; ECK1949 rcsA; ECK2023 ugd; ECK2273 nuoK; ECK3141 yhbO; and ECK3564 yiaK.
  • the present disclosure provides a plasmid for producing RNA produced using the E. coli or composition of the present disclosure.
  • the structural features of the plasmid disclosed herein include, but are not limited to, the following: it is composed of a plasmid replication origin, a drug resistance gene, an RNA polymerase recognition sequence, a 5'UTR, a translation region, a 3'UTR, a polyA sequence, and a restriction enzyme recognition sequence for linearization, and has a circular and supercoiled structure. It is sequence-specifically methylated by a methylation enzyme contained in E. coli.
  • the method of producing the plasmid of the present disclosure includes, but is not limited to, the following: E. coli transformed with the plasmid is cultured in a liquid medium. The cultured cells are collected from the culture medium, and the plasmid is extracted from the cells by a method such as the alkaline-SDS method. The extracted plasmid is used as a template plasmid for mRNA synthesis after E. coli-derived substances are completely removed by a method such as hydrophobic chromatography or cesium chloride density gradient centrifugation.
  • RNA RiboMAX Express Large Scale RNA Production System (Promega), CUGA7 in vitro Transcription Kit (Nippon Gene), Takara IVTpro mRNA Synthesis System (Takara), ScriptMAX Thermo T7 Transcription Kit (Toyobo), etc. are commercially available, but are not limited thereto), or can be incorporated as part of an RNA production device.
  • IVT in vitro transcription
  • the structure of such an RNA manufacturing device is exemplified as follows:
  • the exemplified RNA manufacturing device has a heating and cooling function to keep the temperature constant, and a stirring function to homogenize the solution in the device. It has a sealed structure to prevent the template plasmid, IVT reaction reagents, and newly synthesized RNA in the device from decreasing in function due to decomposition, etc.
  • polyA deletion for mRNA production is 50% or less, for example, polyA deletion can be about 10% or less, about 20% or less, about 30% or less, about 40% or less, about 50% or less, about 60% or less, about 70% or less, about 80% or less, about 90% or less, etc.
  • a composition for mRNA production is provided, in which the plasmid has a polyA deletion of about 50% or less, for example, polyA deletion can be about 10% or less, about 20% or less, about 30% or less, about 40% or less, about 50% or less, about 60% or less, about 70% or less, about 80% or less, about 90% or less, etc.
  • These compositions or plasmids can be produced using the technology (such as E. coli or composition) of the present disclosure.
  • the method of producing a template plasmid for RNA production using the E. coli or composition of the present disclosure is the same as the usual method, but it has been demonstrated in the Examples that the topology of the plasmid prepared from the RPPI gene-disrupted strain by a simple method (miniprep) and a purification method (cesium chloride density gradient centrifugation) has a higher content of DNA that is thought to be dimerized and/or supercoiled compared to the parent strain ( Figure 3).
  • Such a topology is advantageous in that it has a high transcription efficiency of mRNA.
  • the degree of plasmid showing this topology is characterized by being about 20% or more, and for example, dimerization can be about 20% or more, about 30% or more, about 40% or more, about 50% or more, etc.
  • plasmids with these properties directly contribute to high-yield translation synthesis of high-quality RNA with long polyA chains, making these plasmids useful for RNA production.
  • the difference in plasmid topology contributes to the usefulness of this E. coli, plasmid, and composition as an RNA production method.
  • the pDNA of the present disclosure has untranslated regions (UTRs) on both sides of the coding region of the mRNA.
  • UTRs untranslated regions
  • Any UTR may be used, but the 5'UTR may be any UTR that encodes GAPDH, HSD17B4, PSMB3, RPL31, RPL32, RPL35, RPL21, Albumin7, LDHB, ACAT2, ATP5A1, Ndufa4, Mp68, NOSIP, SLC7A3, TUBB4B, UBQLN2, mRPL35A, mRPL21, AIG1, COX6C, ⁇ -globin, ⁇ -globin, RPS8, TOP, MCP-1, RPL12s.c., Ang-2, HSP70, H3.3.
  • the 3'UTR may be selected from GAPDH, Albumin, LDHB, ACAT2, ⁇ -globin, ⁇ -globin, PSMB3, CASP1, COX6B1, GNAS, NDUFA1, and RPS9, histone stem loop, or a natural or artificial sequence having complementarity to the 5'UTR.
  • the pDNA of the present disclosure is a nucleic acid construct that includes a 5' untranslated region (UTR) and a 3' UTR that are at least partially complementary to each other.
  • UTR 5' untranslated region
  • 3' UTR that are at least partially complementary to each other.
  • at least one UTR includes a non-complementary portion and a complementary portion to the other UTR, and the non-complementary portion and the complementary portion may alternate.
  • the complementarity rate is 40% or more and 90% or less (for example, but not limited to, 40%, 50%, 60%, 70%, 80%, 90% or ranges therebetween), and more preferably 75% or more.
  • the non-complementary portions are all 1-base substitutions and the complementary portions are each independently 3 to 7 bases long (e.g., 3, 4, 5, 6, or 7 bases long), those in which the non-complementary portions are all 2-base substitutions and the complementary portions are each independently 5 to 7 bases long (e.g., 5, 6, or 7 bases long), those in which the non-complementary portions are all 2-base removals and the complementary portions are each independently 5 to 11 bases long (e.g., 5, 6, 7, 8, 9, 10, or 11 bases long), those in which the non-complementary portions are all 3-base substitutions and the complementary portions are each independently 8 to 9 bases long (e.g., 8 or 9 bases long), and those in which the non-complementary portions are all 3-base removals and the complementary portions are each independently 8 to 11 bases long (e.g., 8, 9, 10, or 11 bases long).
  • the 3' end of the 3'UTR can be selected as a polyA tail.
  • This polyA tail functions to improve mRNA stability and translation efficiency.
  • the pDNA of the present disclosure has a polyA sequence.
  • the length of the polyA sequence is about 20 to about 600 nucleotides, preferably about 120 to about 200 nucleotides, with a lower limit of about 20 bp, about 30 bp, about 40 bp, about 50 bp, about 60 bp, about 70 bp, about 80 bp, about 90 bp, about 100 bp, about 110 bp, about 120 bp, about 130 bp, about 140 bp, about 150 bp, etc., and an upper limit of about 600 bp, about 550 bp, about 500 bp, about 450 bp, about 400 bp, about 350 bp, about 300 bp, about 250 bp, about 200 bp, etc.
  • the polyA sequence is deleted in about 50% of the plasmids.
  • This disclosure illustrates that the deletion of polyA sequences is suppressed by up to 20% using the same plasmid and culture conditions, and it is understood that similar effects are exhibited in other strains.
  • the design of the plasmid for RNA production may be general, but if a template plasmid with a sequence designed so that the 5' and 3' UTRs are partially complementary is cultured in an RPPI gene disruptant, it will be more useful as it will further increase mRNA production.
  • the complementarity rate is 40% or more and 90% or less (for example, but not limited to, 40%, 50%, 60%, 70%, 80%, 90% or values in between), and more preferably 75% or more.
  • the non-complementary portions are all 1-base substitutions and the complementary portions are each independently 3 to 7 bases long (e.g., 3, 4, 5, 6, 7 bases or a range therebetween); those in which the non-complementary portions are all 2-base substitutions and the complementary portions are each independently 5 to 7 bases long (e.g., 5, 6, 7 bases); those in which the non-complementary portions are all 2-base removals and the complementary portions are each independently 5 to 11 bases long (e.g., 5, 6, 7, 8, 9, 10, 11 bases); those in which the non-complementary portions are all 3-base substitutions and the complementary portions are each independently 8 to 9 bases long (e.g., 8, 9 bases); and those in which the non-complementary portions are all 3-base removals and the complementary portions are each independently 8 to 11 bases long (e.g., 8, 9, 10, 11 bases).
  • the present disclosure provides a method for producing RNA using the plasmid of the present disclosure. That is, mRNA is transcribed and synthesized based on the plasmid obtained in the present disclosure.
  • the method for transcription and synthesis may be any method known in the art. (For example, E T Schenborn and R C Mierendorf, Jr., Nucleic Acids Res. 1985, 13, 6223-6236.; D A Melton, P A Krieg, M R Rebagliati, T Maniatis, K Zinn, M R Green, Nucleic Acids Res. 1984, 12, 7035-56; J F Milligan 1, D R Groebe, G W Witherell, O C Uhlenbeck, Nucleic Acids Res. 1987, 15. 8783-98. ).
  • strains, compositions, and plasmids disclosed herein can be used to produce any RNA, but in this disclosure, the usefulness of RPPI gene disruption is evaluated by the binding of thioflavin T to RNA, and since thioflavin T selectively binds to the polyA of RNA (Nucleic Acids Res. 2015, 43(14), e92), it is particularly useful for producing RNA with a polyA tail, such as mRNA.
  • the present disclosure provides a plasmid characterized by low polyA depletion for mRNA production, the extent of which is described elsewhere herein.
  • the plasmid of the present disclosure can be used to produce all RNAs.
  • non-coding RNAs with polyA are known, and the technology is useful for producing these.
  • the functions of non-coding RNAs are largely unknown, there are some cases where they have been reported to be associated with diseases. They can be applied to RNA medicines. Strains that can achieve increased RNA synthesis yields are also useful for non-coding RNAs that do not have polyA.
  • the present disclosure is particularly useful for producing mRNAs. Although there are some exceptions (such as histone mRNA), mRNAs have a polyA tail at the 3' end.
  • the present invention can suppress the loss of polyA sequences in the plasmid, and the polyA sequence of the produced mRNA is long, making it an advantageous method for producing mRNA formulations.
  • the technology of the present disclosure is useful when synthesizing RNA with polyA.
  • non-coding RNAs with polyA are known, and the present disclosure is also useful in this case.
  • the present disclosure provides RNA produced using the plasmid described in the present disclosure or by the method described in the present disclosure.
  • the composition containing the produced RNA has 1) a low rate of contamination with mRNA lacking polyA. 2) The relative amount of impurities can be reduced due to the increase in the yield of RNA synthesis. This allows for the simplification of subsequent purification steps.
  • the present disclosure may be used in the production of E. coli and, in some cases, in screening (quality standards).
  • the gene deletion strain of E. coli used in the present disclosure may be prepared, for example, by replacing the translation region of the relevant gene with a kanamycin resistance gene or a chloramphenicol resistance gene.
  • the prepared E. coli may be cultured in a medium containing a drug and made into a competent cell by a conventional method.
  • the competent cell may be transformed by a conventional method with a plasmid containing a designed and constructed template DNA for mRNA production.
  • the transformed E. coli may be cultured, and the plasmid may be recovered from the E. coli by a method such as bacteriolysis or disruption.
  • the plasmid is purified and linearized, and used as a template DNA to produce mRNA by transcription synthesis using the IVT method.
  • the mRNA provided by the plasmid and the production method thereof of the present disclosure can be used as an active ingredient for mRNA pharmaceuticals, particularly pharmaceuticals such as infectious disease vaccines, cancer vaccines, and replacement protein therapies.
  • the E. coli of the present disclosure can be used, for example, in the production of mRNA medicines.
  • "Creation, culture, and transformation of E. coli gene-disrupted strain” E. coli with the RPPI gene described in this patent is cultured to make it competent cells, which are then transformed with a separately designed and prepared plasmid for producing mRNA medicines.
  • the resulting transformed strain is used as an industrial production strain, and seed culture and production culture are performed in a culture size appropriate for the purpose, and the cells are collected and lysed to recover and purify the plasmid.
  • RNA is produced by a method such as in vitro transcription using T7 RNA polymerase. This can be purified and subjected to the necessary specification analysis to become the raw material for mRNA medicines.
  • Example 1 Preparation of a gene-disrupted strain of E. coli for preparing a template plasmid DNA suitable for mRNA production (Preparation of plasmid for evaluating mRNA synthesis amount)
  • a plasmid (pT7_TLpA_5Pf_E2Crimson_3Pf_pA200) consisting of a T7 promoter sequence, a Kozak sequence, a fluorescent protein E2Crimson translation region, a stop codon and a 201-base-long polyA consecutive sequence was prepared by inserting a 54-base-long polyA consecutive sequence twice into the BsmBI site of pT7_TLpA_5Pf_E2Crimson_3Pf_pA100 (cited in Japanese Patent Application No. 2023-13390 by the same applicant, and all of the descriptions hereof are incorporated by reference in their entirety in the present disclosure).
  • pT7_TLpA_5Pf_E2Crimson_3Pf_pA100 was constructed as follows.
  • the Pfizer 5'UTR sequences are SEQ ID NOs: 4 and 5: AAGGGAGAATAAACTAGTATTCTTCTGGTCCCCACAGACTCAGAGAGAACCC (SEQ ID NO: 4) TGGCGGGTTCTCTCTGAGTCTGTGGGGACCAGAAGAATACTAGTTTATTCTC (SEQ ID NO:5)
  • the synthetic oligonucleotides shown in SEQ ID NO: 9 and SEQ ID NO: 10 were annealed to obtain the pT7_TL_5Pf_E2Crimson_pA100 plasmid.
  • the DNA fragment was inserted into the BsaI site of pT7_TL_E2Crimson_pA100 to construct the pT7_TL_5Pf_E2Crimson_pA100 plasmid.
  • the Pfizer 3'UTR sequence is SEQ ID NO: 9, SEQ ID NO: 10, which is partially complementary at the 3' end.
  • the Pfizer 3'UTR sequence obtained by treating the pBR-3Pf plasmid with BsaI was inserted into the PaqCI site of pT7_TL_5Pf_E2Crimson_pA100 to construct pT7_TLpA_5Pf_E2Crimson_pA100 (SEQ ID NO: 8). (SEQ ID NO:8)
  • the polyA repeat sequence was inserted using the GoldenGate method described below.
  • a plasmid (pBR-pA50-BsaI) containing a 54-base-long polyA repeat sequence was constructed by annealing the partially complementary synthetic oligonucleotides shown in SEQ ID NOs: 1 and 2, converting the single-stranded portion to double strands using a polymerase extension reaction from 5' to 3' using KOD-Plus-Ver. 2 (Toyobo), and inserting the resulting product into the XcmI site of the pBR322_ ⁇ typeIIS plasmid.
  • a 54-base polyA continuous sequence was inserted into pT7_TLpA_5Pf_E2Crimson_3Pf_pA100 by repeating 80 cycles of incubation at 37°C for 1 minute and 16°C for 1 minute under the conditions of 1 ng/ ⁇ g BsmBI-treated pT7_TLpA_5Pf_E2Crimson_3Pf_pA100, 1 ng/ ⁇ g pBR-pA50-BsaI, 1x T4 DNA ligase included buffer, 23 U/ ⁇ l T4 DNA ligase (Takara Bio), and 0.67 U/ ⁇ l BsaI-HF-v2 (New England Biolab). This procedure was repeated twice to create pT7_TLpA_5Pf_E2Crimson_3Pf_pA200.
  • ECK0337cynS ECK0416 xseB ECK0448 ybaZ ECK0482ybbJ ECK0506ybbY ECK0671 fur ECK0797ybiO ECK0816 moeB ECK0870macB ECK0899 aroA ECK0974yccZ ECK1012ycdQ ECK1105ycfX ECK1190 ycgV ECK1254 trpA ECK1349ydaE ECK1382 feaB ECK1487 gadB ECK1505 ydeW ECK1529 ydeI ECK1548ydfQ ECK1597 pntB ECK1648rnt ECK1680sufA ECK1690 ydiB ECK1701 ydiA ECK1729cedA ECK1743 astB ECK1752ynjB ECK1770ydjH ECK1788 yeaM ECK1834 yeb
  • E. coli strains were cultured in 300 ⁇ l of SOB medium containing 25 ⁇ g/ml kanamycin or 12.5 ⁇ g/ml chloramphenicol at 37°C for 15 hours with a medium-sized thermostatic shaking incubator BR-53FP (Taitec) at a rotation speed of 220 rpm. 300 ⁇ l of SOB medium was mixed with 10 ⁇ l of the above culture solution and cultured with shaking at 37°C for another 3.5 hours, then left to stand on ice for 30 minutes. After cultivation, E. coli was recovered by centrifugation (5,000 x g, 4°C, 5 minutes), and competent cells were prepared according to the instructions for Mix & Go E. coli Transformation Buffer Set (Zymo Research).
  • Example 2 Production of plasmid for mRNA production
  • Preparation of template plasmid for mRNA synthesis When plasmids were prepared from a small number of strains, the plasmids were prepared (miniprep plasmids) using a QIAprep Spin Miniprep Kit and a nucleic acid extraction and purification apparatus QIAcube (Qiagen) according to the manufacturer's instructions.
  • a 96-well DNA binding unifilter (Cytiva) was used as follows: The recovered E. coli cells were stirred in a vortex mixer with 100 ⁇ l of Buffer P1 (Qiagen) containing 10 ⁇ g/ml ribonuclease A (Nacalai) for 1 minute, and then 100 ⁇ l of Buffer P2 (Qiagen) was added to completely dissolve the cells. 140 ⁇ l of Buffer P3 (Qiagen) was added to this solution and stirred gently for 10 seconds, after which 20 ⁇ l of chloroform (Nacalai) was added and the solution was stirred in a vortex mixer for 10 seconds.
  • Buffer P1 Qiagen
  • Buffer P2 Qiagen
  • the aggregates formed during this procedure were removed by centrifugation (5,000 rpm, 5 minutes) to obtain a plasmid extract.
  • This extract was added to a 96-well DNA binding unifilter and centrifuged (3,000 rpm, 5 minutes) to adsorb the plasmid onto the filter.
  • the filter was washed twice with 250 ⁇ l of Buffer PB (Qiagen) and twice with 250 ⁇ l of Buffer PE (Qiagen), after which the plasmid was eluted with 20 ⁇ l of TE buffer (Nacalai).
  • the washing and elution procedures were carried out by centrifugation (3,000 rpm, 5 minutes).
  • This mixture was centrifuged at 50,000 rpm and 18°C for more than 15 hours in a floor-type ultracentrifuge Optima XE (Beckman Coulter), and the band of supercoiled circular plasmid was collected under ultraviolet light (365 nm).
  • the collected solution was mixed thoroughly with 1 ml of 1-butanol, then centrifuged (8,000 ⁇ g, 10 min) to separate into 1-butanol and aqueous phases, and the separated 1-butanol phase was removed. This series of operations was repeated 5-10 times to remove ethidium bromide. 200 ⁇ l of Buffer P3 was added to this solution, and distilled water was added to make the total volume 3 ml.
  • Example 3 RNA production according to the present disclosure (In vitro transcription with T7 RNA polymerase)
  • the template plasmid was linearized with the restriction enzyme BsmBI in order to terminate RNA synthesis by dissociating RNA polymerase from the template DNA and to make the 3' end of the synthesized RNA an A nucleotide sequence.
  • BsmBI treatment the plasmid was added with TE-saturated phenol, mixed thoroughly, and then centrifuged (20,000 ⁇ g, 10 minutes) to separate it into an organic phase and an aqueous phase, and the aqueous phase was recovered in a new tube.
  • the recovered aqueous phase was added with 1-butanol, mixed thoroughly, and then centrifuged (20,000 ⁇ g, 10 minutes) to separate it into a 1-butanol phase and an aqueous phase, and the separated 1-butanol phase was removed. This operation was repeated three times to completely remove phenol and reduce the volume of the aqueous phase.
  • the aqueous phase was added with 3M sodium acetate solution (pH 5.2) (Nacalai) and ethanol, mixed thoroughly, and then centrifuged (20,000 ⁇ g, 10 minutes) to precipitate the DNA fragments. The precipitated DNA fragment was washed with 70% ethanol and then dissolved in distilled water to obtain linear template DNA.
  • the in vitro transcription reaction was carried out by incubating 50 ng linear template plasmid, 1x T7 RNA polymerase attached buffer (Takara Bio), 5 mM DTT, 0.2 mM CleanCap (TriLink), 0.05 mM GTP, 0.25 mM ATP, 0.25 mM CTP and 0.25 mM N1-methyl pseudo UTP (Yamasa Shoyu), 1 U/ ⁇ l Recombinant RNase Inhibitor (Takara Bio), and 1.25 U/ ⁇ l T7 RNA polymerase (Takara Bio) on a 384-well black microplate (Greiner) at 37°C for 3 hours. The reaction was stopped by adding EDTA to a final concentration of 3.3 mM.
  • the mRNA synthesis evaluation value was calculated by the method described in Example 10 described below. That is, after the reaction was stopped, thioflavin T (FUJIFILM Wako Pure Chemical Industries, Ltd.) was added to the reaction solution to a final concentration of 25 ⁇ M, and the fluorescence intensity was measured at an excitation wavelength of 438 nm and a fluorescence wavelength of 491 nm using a plate reader Infinite 200 PRO (TECAN). The fluorescence measurement value of the JM109 strain was set to 1, and the fluorescence measurement value of the aforementioned E. coli strain was used as the mRNA synthesis evaluation value (FIG. 1 (FIG. 1-1 and FIG. 1-2)).
  • Example 4 Characterization (Plasmid topology, polyA sequence analysis) (Plasmid topology, polyA sequence analysis) The plasmids were analyzed by agarose gel electrophoresis prepared using UltraPure Agarose (Thermo Fisher) and 1 ⁇ TAE buffer (Nacalai).
  • a 490 bp DNA fragment containing the polyA sequence was first prepared by treating with the restriction enzymes BsmBI (New England Biolab) and XhoI (New England Biolab). This DNA fragment was separated by electrophoresis on a 3% agarose gel at a voltage of 135 V for 25 minutes. Furthermore, electrophoresis for calculating the polyA deletion rate was performed using a 2100 Bioanalyzer Electrophoresis System and a DNA1000 Kit (Agilent Technologies) according to the manufacturer's instructions.
  • Example 5 Preparation of two-gene disruption strain
  • E. coli JM109 strain the following two genes were replaced with a kanamycin resistance gene or a chloramphenicol resistance gene to prepare a two-gene disruptant strain.
  • Example 6-1 Preparation of a gene-disrupted strain using E. coli DH5 ⁇ as a parent strain and production and evaluation of a plasmid for mRNA production
  • E. coli DH5 ⁇ strain Toyobo
  • ECK2023ugd ECK2273 nuoK Gene disruption strains were prepared by replacing each of the genes with a kanamycin resistance gene.
  • the mRNA synthesis evaluation values of these gene disruption strains were calculated by the method described in Example 10, and the results are shown in Figure 5. An increase in the mRNA synthesis evaluation value was observed in these gene disruption strains.
  • Example 6.2 Creation of gene disruption strains in other E. coli strains
  • the plasmid described in Example 5 is transformed into E. coli strains other than JM109 and DH5 ⁇ , namely, BL21, SCS1, XL1-blue, and HB101.
  • the specific procedures are similar to those in the above-mentioned Examples.
  • These strains are available from Takara Bio and Agilent Technologies.
  • the BL21 strain is available from Takara Bio, New England Biolab, Nippon Gene, BioDynamics Institute, Agilent Technologies, Promega, etc.
  • the SCS1 strain is available from Agilent Technologies.
  • the XL1-blue strain is available from Agilent Technologies, Nippon Gene, Bio Elegen Technology, etc.
  • the HB101 strain is available from Takara Bio, Promega, Nippon Gene, etc.)
  • a plasmid is obtained from the resulting transformed strain, and this is transcribed into mRNA, confirming that the strain has a high mRNA production ability, similar to the JM109 strain.
  • Example 7 Preparation of cell lines for mRNA drug production
  • a plasmid for producing an mRNA pharmaceutical is prepared in the same manner as in the plasmid for evaluating the amount of mRNA synthesis described in Example 1, in which a gene translation region encoding a protein such as SARS-CoV-2 spike protein, HIV spike protein, HIV envelope glycoprotein, influenza HA protein, HSV-2 glycoprotein, ornithine transcarbamylase OCT, CFTR, OX40 ligand, IL-2, IL-7, IL-12, IL-23, VEGF-A, GM-CSF, IFNalpha, chimeric antigen receptor CAR, NY-ESO-1, PD-L1, WT-1, or MAGE-3, which is an antigen to be used as an mRNA pharmaceutical, is incorporated instead of the fluorescent protein E2Crimson.
  • a protein such as SARS-CoV-2 spike protein, HIV spike protein, HIV envelope glycoprotein, influenza HA protein, HSV-2 glycoprotein, orn
  • E. coli in which the RPPI genes described herein (ECK1949 (rcsA), ECK2023 (ugd), ECK2273 (nuoK)) have been disrupted is cultured to prepare competent cells, which are then transformed with a plasmid for producing mRNA pharmaceuticals.
  • RNA is produced by in vitro transcription using T7 RNA polymerase. This is purified and subjected to the necessary specification analysis to produce the raw material for mRNA drugs.
  • Example 10 Calculation of mRNA synthesis evaluation value
  • the calculation of the mRNA synthesis evaluation value employed in the present specification including the examples will be described below.
  • the mRNA synthesis evaluation value is an index that uses this thioflavin to evaluate both the amount of mRNA synthesis and the length of the mRNA polyA chain.
  • the fluorescence intensity generated by Thioflavin T binding to mRNA transcribed and synthesized using as a template a plasmid prepared from a gene-disrupted strain transformed with a plasmid containing an open reading frame (ORF) that codes for a specific protein mRNA is measured, and the value can be calculated as a relative value when the value of mRNA transcribed and synthesized from a standard E. coli-derived plasmid is set to 1.
  • E. coli in which the RPPI gene has been artificially disrupted as a strain for producing template plasmid DNA, it is possible to produce high-yield, high-quality mRNA, making it useful in the biotechnology and pharmaceutical industries.
  • SEQ ID NO: 1 Synthetic oligonucleotide for producing pBR-pA50-BsaI
  • SEQ ID NO: 2 Synthetic oligonucleotide for producing pBR-pA50-BsaI
  • SEQ ID NO: 3 pT7_TLpA_5Pf_E2Crimson_3Pf_pA200
  • SEQ ID NO: 4 Pfizer 5'UTR sequence
  • SEQ ID NO: 6 Primer Common-F
  • SEQ ID NO: 7 Primer Common-R
  • SEQ ID NO: 8 pT7_TLpA_5Pf_E2Crimson_3Pf_pA100
  • SEQ ID NO: 9 Pfizer 3'UTR sequence
  • SEQ ID NO: 10 Pfizer 3'UTR sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/JP2024/029712 2023-08-22 2024-08-21 リボ核酸生産技術 Ceased WO2025041806A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025541533A JPWO2025041806A1 (cg-RX-API-DMAC7.html) 2023-08-22 2024-08-21

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-135083 2023-08-22
JP2023135083 2023-08-22

Publications (1)

Publication Number Publication Date
WO2025041806A1 true WO2025041806A1 (ja) 2025-02-27

Family

ID=94731882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2024/029712 Ceased WO2025041806A1 (ja) 2023-08-22 2024-08-21 リボ核酸生産技術

Country Status (2)

Country Link
JP (1) JPWO2025041806A1 (cg-RX-API-DMAC7.html)
WO (1) WO2025041806A1 (cg-RX-API-DMAC7.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022541287A (ja) * 2019-07-19 2022-09-22 インバイオス エン.フェー. 宿主細胞におけるフコシルラクトースの産生
JP2023517682A (ja) * 2020-03-11 2023-04-26 ネイチャー テクノロジー コーポレーション 細菌宿主株

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022541287A (ja) * 2019-07-19 2022-09-22 インバイオス エン.フェー. 宿主細胞におけるフコシルラクトースの産生
JP2023517682A (ja) * 2020-03-11 2023-04-26 ネイチャー テクノロジー コーポレーション 細菌宿主株

Also Published As

Publication number Publication date
JPWO2025041806A1 (cg-RX-API-DMAC7.html) 2025-02-27

Similar Documents

Publication Publication Date Title
US12203105B2 (en) Engineered strain for producing allulose and derivatives thereof, method for construction therefor and use thereof
Cimini et al. Homologous overexpression of rfaH in E. coli K4 improves the production of chondroitin-like capsular polysaccharide
WO2018171747A1 (zh) 一种体外DNA-to-Protein(D2P)的合成体系、制剂、试剂盒及制备方法
US20220259631A1 (en) Production of fucosyllactose in host cells
KR20230020991A (ko) 최적화된 뉴클레오티드 서열의 생성
WO2025231937A1 (zh) 一种不产生免疫原性副产物、具备高转录活性的t7 rna聚合酶突变体与应用
CN111073871B (zh) 热稳定性提高的dna聚合酶突变体及其构建方法和应用
CN120905182B (zh) Rna聚合酶变体及其应用
US20240417770A1 (en) mRNA Capping Enzyme And Methods of Use Thereof
CN108998401B (zh) 一种生产3-氨基异丁酸的方法
JP2022535651A (ja) 好熱性タンパク質を利用した組換えインビトロ転写及び翻訳のための系、方法及び組成物
CN114891707A (zh) 重组菌株及其全细胞催化生产胆红素的方法
JP7048643B2 (ja) 無細胞タンパク質合成のためのプロモーター構築物
JP6249456B2 (ja) 藍藻においてプラスチック原料を生産する方法
WO2023098036A1 (zh) Taq酶突变体、其制备方法和应用
CN116355875B (zh) 甲硫氨酸腺苷基转移酶突变体及其在生产s-腺苷甲硫氨酸中的应用
EP4150072A1 (en) Systems and methods for enhancing gene expression
CN110305855B (zh) 天麻GeCPR基因及其应用
CN116064355B (zh) 一种生产β-烟酰胺单核苷酸的重组菌株及其应用
CN108424859B (zh) 生产胞磷胆碱的基因工程菌的构建与应用
DK2254994T3 (en) Compositions and methods of amino acid biosynthesis
CN113403243B (zh) 基于lux报告系统的猪链球菌发光菌及其构建方法
CN119193529B (zh) 一种t7 rna聚合酶突变体及其制备与应用
Fung et al. Harnessing xylitol utilization in Escherichia coli for antibiotic-free plasmid and recombinant protein production
CN113528366A (zh) 一种产beta-丙氨酸酵母菌及其构建方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24856494

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2025541533

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025541533

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE